226 results about "Phosphatidylcholine" patented technology

The invention belongs to the field of enzymatic preparation of structural phospholipids, and particularly relates to a method for preparing phosphatidylserine through interfacial enzyme catalysis. A series of high-activity immobilized phospholipase are prepared by innovatively adopting bifunctional group modified hollow mesoporous silica microspheres as a carrier and adsorbing immobilized phospholipase D. The catalyst has the functions of a catalyst and an emulsifier, and a Pickering emulsion interfacial enzyme catalysis system can be efficiently constructed. In the system, the phosphatidylcholine and the serine are efficiently converted into the phosphatidylserine through a phosphatidyl transfer reaction, the conversion rate of the phosphatidylserine within 20 minutes can reach 85%-95%, and the catalytic efficiency reaches up to 372 mmol / (g.h). In addition, after the catalyst is recycled for 10 times, the conversion rate is still kept at 70.9%, and the catalyst shows excellent stability and reusability. The method has the remarkable advantages of being mild in reaction condition, high in catalytic efficiency, capable of being repeatedly used and the like, and a new technical approach is provided for industrial production of phosphatidylserine.

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.

The invention discloses a preparation method of a composite spray for improving the hemostatic ability of a wound part, the composite spray comprises a liquid A and a liquid B. The liquid B is a sodium alginate aqueous solution, a preparation method of the solution A comprises the following steps: 1, dissolving a lipopeptide conjugate, cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidylserine and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2, preparing the mixed system into a precursor solution by utilizing a film hydration method; 3, adding calcium chloride into the precursor solution, and reacting in a dark place to obtain a solution A; a precursor solution is designed according to the function of natural platelets, the function of the precursor solution is equivalent to that of nano platelets, the precursor solution is matched with sodium alginate, adverse effects on a blood coagulation system caused by fibrin degradation, platelet activation capability reduction and the like of a wound part due to blood loss can be relieved in a targeted manner, and the preparation has the advantages of rapid hemostasis, good biological activity, no toxic or side effects and the like. And the wound healing is rapid.

An mRNA vaccine encapsulated with lipid nanoparticles for PDCoV, a preparation method and an application thereof are provided, and the mRNA vaccine for PDCoV includes at least one of sequences as described in SEQ ID NO: 1-2; the lipid nanoparticle-encapsulated mRNA vaccines includes the mRNA vaccine, and lipids for encapsulating the mRNA vaccine, and the lipids are formed by mixing ionizable liposome, distearoyl phosphatidylcholine, cholesterol and PEG liposome.

The invention provides a metabolic marker combination for ovarian cancer diagnosis and application thereof, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for ovarian cancer diagnosis. The metabolic marker combination comprises phosphatidylcholine 34: 4, threonic acid, phosphatidylcholine 32: 2, pyroglutamic acid, phosphatidylcholine 36: 6 and ceramide d38: 2. According to the metabolic marker combination, plasma samples of a healthy subject and an ovarian cancer patient are analyzed, a group of biomarkers with significant difference are screened from the plasma samples, and the metabolic marker combination is a non-invasive, non-invasive and high-accuracy metabolic marker combination for distinguishing the healthy subject and the ovarian cancer patient. The method can be used for constructing a diagnostic model for distinguishing healthy subjects from ovarian cancer patients. The metabolic marker combination disclosed by the invention can be used for improving the diagnosis and evaluation capability of ovarian cancer patients, so that early discovery, early diagnosis and early intervention can be realized clinically, and the survival rate of the ovarian cancer patients is improved.

The invention discloses a calcium liposome for promoting bone health as well as a preparation method and application thereof. The calcium liposome is prepared from the following components in parts by weight: 3 to 7 parts of phospholipid composition, 0.1 to 0.35 part of phytosterol, 1 to 5 parts of insoluble calcium, 1 to 7.5 parts of protein and 0.1 to 1 part of modifier, wherein the phospholipid composition consists of egg yolk lecithin, phosphatidylinositol and distearoyl phosphatidylcholine, and the mass ratio of the egg yolk lecithin to the phosphatidylinositol to the distearoyl phosphatidylcholine is (8-12): (7-11): ( The specific phospholipid composition obtained through screening is combined with phytosterol to serve as a membrane material to wrap a compound of insoluble calcium and protein, so that the dispersity and the stability of the prepared calcium liposome are obviously improved, when the calcium liposome is applied to preparation of calcium soft capsules, the oil leakage phenomenon is obviously reduced, meanwhile, the absorption of an organism to calcium is also enhanced, and the bioavailability of the calcium soft capsules is improved. Particularly, the bone mineral density and the bone calcium content of an organism are obviously increased, healthy development of bones is promoted, and the difficulty and the pain point of insoluble calcium applied to the fields of functional foods, health care products, biological medicines and the like are effectively solved.

The invention discloses a preparation method of high-purity polyene phosphatidylcholine (PC) euphausia superba oil. Edible ethanol alcohol-soluble euphausia superba oil (the phospholipid content of the oil is 40-60%, the PC content of the phospholipid is about 80%, and the euphausia superba oil is a product obtained by carrying out preliminary impurity removal and fishy smell removal on a crude euphausia superba oil product obtained by carrying out crude extraction by using ethanol) is used as a raw material, an AO material (an adsorbent prepared by taking aluminum oxide as a main material and adding a small amount of silica gel) is used as an adsorbent, and absolute ethanol is used as a percolation eluting agent to prepare a phosphorus oil product of which the PC is greater than or equal to 97%. The method is characterized in that (1) alcohol-soluble krill oil in which most non-phospholipid impurities are removed is adopted as a raw material of an upper percolation column liquid, so that the purity of a subsequent product is ensured; (2) an AO material (mainly composed of alumina and added with a small amount of an adsorbent prepared from silica gel) is subjected to a high-temperature dehydration process, so that the separation capacity of a chromatographic agent is improved; and (3) single absolute ethyl alcohol is adopted as percolating liquid, so that the method is green and environment-friendly. And (4) the large-diameter percolation column is adopted, so that industrial-scale production can be realized. The method is simple in process, high in product purity and suitable for large-scale industrial preparation of the krill oil product of polyene phosphatidylcholine.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

The invention belongs to the field of substance content detection, and discloses a method for determining the content of soybean phosphatidylcholine or phosphatidylethanolamine in a soft capsule, which comprises the following steps: (1) preparing a soybean phosphatidylcholine or phosphatidylethanolamine standard solution; (2) preparing a to-be-detected sample solution; (3) performing high performance liquid chromatography analysis; (4) drawing a standard curve; and (5) calculating the content of soybean phosphatidylcholine or phosphatidyl ethanolamine. The method has the advantages of high response value, short retention time and stable base line, and is not interfered by other components in the soft capsule; the method has the advantages of simple operation, high precision and good repeatability, the recovery rate meets the analysis requirement, and the method can efficiently, quickly and accurately detect the content of two components, namely soybean phosphatidylcholine and phosphatidyl ethanolamine, of soybean phospholipid in the soft capsule content.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The invention provides a nano drug delivery system, which comprises (a) an active component, which comprises an anti-tumor active substance or a mixture of the anti-tumor active substance and a substance capable of synergistically generating an anti-tumor effect with the anti-tumor active substance; (b) a carrier material, wherein the carrier material comprises an mPEG-PLGA-HA material which is modified or not modified with a PD-1 or PD-L1 monoclonal antibody; optionally (c) a lipid material selected from the group consisting of lecithin (PC), cephalin (PE), mPEG-PE, mPEG-DSPE, mPEG-DPPE, DOP-DEDA, or a combination thereof; and the active ingredient is wrapped by the carrier material. The nano drug delivery system has transmembrane capability, and can deliver active components to the outside of cells, cytoplasm and / or cell nucleus.

The invention relates to the technical field of biotechnology and medical detection, in particular to an ovarian cancer early-stage accurate screening method based on triple lipid metabolite chemical crosslinking, which comprises the following steps: sample collection: collecting a serum sample of a person to be detected; lipid metabolite extraction: extracting lipid metabolite from the serum sample; detection of triple lipid metabolites: simultaneously detecting the contents of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) in the lipid metabolites by adopting a liquid chromatography-mass spectrometry technology, and by simultaneously detecting the three lipid metabolites of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) and carrying out chemical cross-linking analysis, the content of the triple lipid metabolites in the lipid metabolites can be detected; and calculating the triple lipid metabolite index (TLMI), so that the abnormal lipid metabolism condition of the ovarian cancer patient can be more comprehensively and accurately reflected, and the sensitivity and the specificity of early screening of the ovarian cancer are improved.

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

The invention belongs to the field of daily chemicals, and discloses a preparation method of a sturgeon caviar extract, which adopts a Soxhlet extraction method and takes ethanol or diethyl ether as a solvent for extraction to obtain the sturgeon caviar extract. According to the sturgeon caviar extract, a Soxhlet extraction method is adopted, ethyl alcohol or diethyl ether is used as a solvent for extraction, the sturgeon caviar extract is obtained, and in the obtained extract, the content of DHA is 3.1-8.1 wt%, the content of vitamin E is 500-1150mu g / g, and the content of phosphatidylcholine is 3-4.8 wt%; the content of effective components is far higher than that of an enzymolysis method. The invention also aims to provide application of the sturgeon caviar extract.

The application belongs to the technical field of anti-aging skin care product preparation, and discloses a composition containing a composite exosome-polypeptide, a preparation method thereof and application of the composition in cosmetics. The composition contains, in terms of mass fraction, 3.0%-7.0% of an exosome-polypeptide composite wrapped by a biomimetic liposome, 4%-9% of a plant active synergistic extract, 15%-20% of a temperature-sensitive moisturizing sustained-release system, 3%-6% of a lipid barrier repair agent, 0.3%-0.8% of an antioxidant stabilizer, and the rest is a basic base; the exosome is composed of membrane pod huangqi root exosome, salvia miltiorrhiza exosome and long life flower exosome; the polypeptide is composed of palmitoyl tripeptide-5 and acetyl hexapeptide-8; and the biomimetic liposome is composed of phosphatidylcholine, ceramide NP and phytosteryl oleate. The application is compounded by the composite exosome-polypeptide-multiple effect component, hierarchical synergy is achieved, multiple-dimensional aging targets are covered, the transdermal rate is improved, the activity is retained for a long time, the barrier repair and skin quality adaptation are considered, and the anti-aging performance is excellent.

The invention relates to a high-absorptivity blood fat reducing composition containing a burdock root water extract as well as a preparation method and application thereof, and relates to the field of preparation of blood fat reducing compositions. The blood fat reducing composition is prepared from burdock root aqueous extract, hawthorn flavone, cassia seed glycoside and phosphatidylcholine according to the mass ratio of (6 to 10): (1 to 2): (0.8 to 1.5): (0.5 to 1). According to the composition, the burdock root aqueous extract is taken as a core, hawthorn flavone, cassia seed glycoside and phosphatidylcholine are matched, and the problems of low absorption rate and single curative effect of the existing traditional Chinese medicine lipid-lowering medicine are solved through the dual design that active ingredients synergistically lower lipid and absorption-promoting ingredients improve bioavailability.

The invention discloses a compound grease feed additive for improving breeding quality of channa maculata and application. The method comprises the following steps: (1) preparing experimental feed; the method comprises the following steps: respectively preparing an experimental group ARA 1.5 added with 1.5% of arachidonic acid and an experimental group ARA + PC added with 1.5% of arachidonic acid and 1.5% of phosphatidylcholine; (2) feeding; (3) after the culture experiment is finished, treating and detecting the channa maculata; (4) carrying out an artificial propagation test; (5) carrying out ovarian steroid synthesis related gene expression detection; and (6) carrying out data statistical analysis. By adding arachidonic acid (ARA) and phosphatidylcholine (PC) into the feed, the breeding performance of channa maculata and the quality of fry are improved, and the feed has very important significance for improving the aquatic product efficiency of high-quality fry of channa maculata in aquaculture.

The present invention provides a nutritional composition comprising milk phospholipids and egg phospholipids, particularly suitable as a nutritional composition for infants, also as a nutritional support product for pregnant women and as a nutritional supplement for the elderly, in which phosphatidylcholine and sphingomyelin and hence choline are also highly correlated. The invention provides a nutritional composition containing choline with high bioavailability.

The application provides a nanoemulsion and a preparation method and application thereof. The total amount of raw materials for preparing the nanoemulsion is 100%, and the raw materials include the following components: 1-40% of a composite surfactant, 1-25% of an oil phase, 1-30% of a co-surfactant, and the balance of a water phase; wherein the mass of the composite surfactant is 100%, and the composite surfactant includes the following components: 5-25% of a biological surfactant, 35-65% of a fatty alcohol polyoxyethylene ether surfactant, 1-20% of dodecyl benzene sulfonic acid and / or sodium salt thereof, 1-20% of oleic acid, and 1-5% of citric acid; the biological surfactant includes one or more than two combinations of sophorolipid, rhamnolipid, trehalose lipid, surfactin, alkyl polyglycoside, phosphatidylcholine, amino acid lipid, saponin, phospholipid, or derivatives thereof; and the average particle size of the emulsion droplets in the nanoemulsion is 1.5-5 nm. The nanoemulsion has excellent recovery performance.

The invention discloses an application of a secretory curl-associated protein 2 gene as a new target for treating uterine scars, the secretory curl-associated protein 2 gene (sFRP2) promotes the progress of the uterine scars, interferes, silences and inhibits the uterine scars, and the sFRP2 is knocked out, so that the occurrence and development of the scar uterus can be relieved, the pregnancy rate of women can be increased, and the adverse pregnancy outcome can be reduced. In order to further improve the curative effect that sFRP2 gene expression is inhibited by sFRP2-targeted small interfering RNA (issFRP2) so as to inhibit uterine scar formation, ionizable lipid, distearoyl phosphatidylcholine (DSPC), cholesterol and 1, 2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol (DMG-PEG) are mixed and dissolved in ethanol according to a certain molar ratio, issFRP2 is dissolved in a citric acid buffer solution, and the issFRP2-targeted small interfering RNA (issFRP2) is added into the citric acid buffer solution so as to obtain a mixed solution; an ethanol phase and a water phase are mixed through a microfluid device, and the mixed solution is dialyzed in a PBS solution for two hours to prepare lipid nanoparticles. And then mixing the polycarbophil, the poloxamer and the lipid nanoparticles to prepare the composite hydrogel. The hydrogel can locally release sisFRP2 in the uterus, inhibit fibrosis, reduce collagen deposition and repair uterine scars. The hydrogel is good in biocompatibility and noninvasive, can realize slow release of the medicine, avoids repeated administration, has no obvious side effect on a maternal body and a fetus, and can also be used for other fibrosis-related diseases.

The present invention relates to the technical field of joint repair hydrogels, and in particular to a three-dimensional biohydrogel and its preparation method and application. The three-dimensional biohydrogel, by weight, comprises: 1-5 parts of methacrylic anhydride hyaluronic acid HAMA, 0.05-0.15 parts of initiator, 3-8 parts of hydrogenated soybean phosphatidylcholine liposomes and 7-13 parts of stem cell solution; the preparation method of the stem cell solution is: gelatin and water are mixed to obtain a gelatin solution; stirring at 40-60 ° C to prepare a dispersed phase; adding an emulsifier to the oil to prepare a continuous phase; the dispersed phase and the continuous phase are prepared by microfluidic technology to obtain uniform droplets, and the droplets are freeze-dried to obtain gelatin microspheres; stem cells are added to the gelatin microspheres and incubated at 25-37 ° C for 2-4 hours to obtain a stem cell solution. The present invention has long-lasting efficacy and significant safety, and can fundamentally repair articular cartilage.

The present invention relates to the field of firefighting technology and provides a pollution-free, dischargeable foam fire extinguishing agent and a preparation method thereof. The raw materials of the foam fire extinguishing agent include the following components by weight: 1-10 parts methyl isobutyl carbinol, 1-3 parts hydrogenated phosphatidylcholine, 1-3 parts poloxamer, 5-10 parts titanium dioxide, 4-8 parts foam stabilizer, 0.5-1 part thickener, 2-4 parts cosolvent, and 70-80 parts water. This technical solution overcomes the problem of existing foam fire extinguishing agents containing fluorocarbon surfactants and having poor fire extinguishing performance.

The invention discloses a lipid nano assembly loaded with a hydrophilic antibacterial drug as well as a preparation method and application of the lipid nano assembly, and belongs to the technical field of biological medicines. The lipid nano assembly loaded with the hydrophilic antibacterial drug is synthesized by combining phosphatidylcholine lipids and phenylboronic acid derivatives through dynamic covalent boric acid ester bonds, and lipid molecules can load hydrophilic antibacterial small molecule drugs. By screening Cip with different concentrations, high drug loading rate and encapsulation rate of Cip are realized. The lipid nano assembly has triple responsiveness of H < + >, H2O2 and ATP, the prepared lipid nano assembly can deliver hydrophilic drugs to a target part, enrichment is achieved at the target part, then controlled release of the drugs is achieved through the special microenvironment of the focus part, and the good treatment effect is achieved.

This invention discloses a soothing and repairing composition and its application, comprising the following raw materials: phytosterols, chamomile extract, hydrolyzed sodium hyaluronate, tocopherol, ceramide NP, triethanolamine, lactobacillus, macadamia seed oil, magnolia alcohol, matricaria flower extract, maltodextrin, lecithin, phosphatidylcholine, ascorbyl palmitate, inulin root juice, arginine / lysine polypeptide, squalane, jojoba seed oil, scutellaria baicalensis root extract, polygonum cuspidatum root extract, fructose, glycerin, p-hydroxyacetophenone, butylene glycol, acrylate / C10-30 alkanol acrylate crosspolymer, α-glucan oligosaccharide, 1,2-hexanediol, and water as the balance. Compared with the prior art, the soothing and repairing composition prepared by this invention has the effects of rapidly rebuilding the skin barrier, regulating skin immune function, improving skin microecology, synergistic effect, and rapid skin repair.

The invention discloses a cell membrane vesicle self-assembly body loaded with spirulina PDRN and a preparation method of the cell membrane vesicle self-assembly body, and belongs to the technical field of cosmetics. The preparation method comprises the following steps: homogenizing and crushing spirulina at low temperature and high pressure, and performing graded filtration to prepare spirulina vesicle suspension; mixing with auxiliary materials such as spirulina platensis source PDRN, hydrogenated soybean phosphatidylcholine and the like to prepare a medicine-carrying vesicle premixed solution; and carrying out pre-homogenization, low-temperature fine homogenization and graded filtration to obtain the target self-assembly body. According to the invention, the spirulina natural cell membrane vesicles are taken as a core carrier, efficient encapsulation of PDRN is realized through membrane fusion recombination, the encapsulation efficiency of the obtained product can reach 55% or more, the transdermal absorption performance is excellent, UVB-induced skin light injury cells can be remarkably repaired, and the product has the effects of resisting aging, tightening, resisting wrinkles and whitening, and can be widely applied to preparation of skin care products.

The invention provides powdery phospholipid with good free-running property and rich phosphatidylcholine as well as a preparation method and application of the powdery phospholipid, and belongs to the technical field of deep processing of phospholipid. According to the method, the crude phospholipid is sequentially subjected to absolute ethyl alcohol purification and acetone refining, the refining frequency is controlled, it is guaranteed that the PC content is 40 wt% or above, meanwhile, the isomaltitol is added in the last time of refining, and the isomaltitol serves as sugar alcohol which is low in hygroscopicity and easy to crystallize, so that the purity of the product is greatly improved. At the moment, a special co-dispersion system which can form with phospholipid in an acetone medium is added, and in the subsequent drying process, the phospholipid particles can be accurately filled and an isolation layer is formed, so that the physical structure of the product is fundamentally changed, and particle adhesion is prevented from internal anti-caking and internal isomaltitol is used as a skeleton; an anti-caking agent is arranged outside to serve as a'ball 'to further reduce friction, and the dual-action mechanism ensures that the final product has extremely excellent flowability and long-term storage stability.

The invention discloses a water-soluble lubricant as well as a preparation method and application thereof. The water-soluble lubricant comprises the following components in percentage by mass: 1.5%-3% of beta-(1, 3) glucan; 3%-5% of polyether modified polydimethylsiloxane; 1.5% to 3% of PEG-40 hydrogenated castor oil; 1%-2% of phosphatidylcholine; 0.1%-0.5% of a thickening agent; and the balance of water. According to the formula of the water-soluble lubricant, a beta-(1, 3) glucan and polyether modified polydimethylsiloxane composite system is adopted, meanwhile, PEG-40 hydrogenated castor oil and phosphatidylcholine are selected to be compounded for use to form a composite emulsification system, a small amount of thickening agent is added, and a high-stability lubricant system is obtained; the problem of phase separation of hydrophobic silicone oil and hydrophilic glucan is effectively solved, and the water-soluble lubricant with excellent lubricating property, rapid water solubility, good biocompatibility and degradability is realized.

The invention relates to the field of phospholipid synthesis, in particular to a preparation method of phosphatidylcholine of saturated fatty acid, which is characterized by comprising the following steps: A, mixing glycerophosphorylcholine, unsaturated fatty acid, a condensing agent, an acid-binding agent and a reaction solvent, and carrying out esterification reaction to obtain an intermediate mixture; b, mixing the intermediate mixture with a metal salt solution, and then performing liquid separation to obtain an organic phase to form a refined mixture 1; c, mixing the refined mixture 1 with water, extracting, separating liquid to obtain an organic phase, and removing a solvent to obtain a refined mixture 2; and D, mixing and separating out the refined mixture 2 and an organic solvent, and carrying out solid-liquid separation and drying to obtain a phosphatidylcholine product. The invention solves the problems of high purification and separation difficulty, high cost and the like in the existing synthesis of phosphatidylcholine.

The invention discloses a biomarker composition for predicting the biological age or aging state of an individual, and the biomarker composition comprises tetracosyl saturated fatty acid / tetracosyl monounsaturated fatty acid phosphatidylcholine (PC 24: 0 / 14: 1), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine- The invention relates to a pharmaceutical composition for the preparation of a pharmaceutical composition, which comprises the following components in parts by weight: 20: 0 / 22: 5, 20 / docosapentaenoic acid monohexosyl sphingosine amide (HexCer 20: 0 / 22: 5), trigonelline, lithocholic acid glycine (Lithocholic acid glycine), and octadecanoic saturated fatty acid / octadecanoic monounsaturated fatty acid phosphatidylcholine (PC 18: 0 / 18: 1). The biomarker can be used for accurately characterizing the aging state of an organism, and provides a strategy for early screening, intervention evaluation, accurate health management and the like of related diseases of the elderly.